Go to the profile of Synplogen

Synplogen

Associate Director, Synplogen

About Synplogen

By the year 2030, production utilizing biotechnology is expected to comprise 2.7% of global gross domestic product, an amount valued at approximately 1.7 trillion USD. This trend is not limited to the medical and food industries, however―the use of biotechnology is anticipated to become commonplace in manufacturing and energy production as well. As mankind faces a plethora of environmental problems and critical issues of a global scale, biotechnology is poised to make enormous contributions towards humanity’s shared future. Thanks to recent advances in synthetic biology, the age is fast approaching where mankind can―through the synthesis of DNA―engineer an unlimited number of biological mechanisms. At the core of synthetic biology is the ability to “read” and “write” DNA, which encodes the information by which biological processes take place. By utilizing Synplogen’s proprietary gene synthesis process, we hope to contribute to the richer future promised by synthetic biology and biotechnology.

Therapeutic Areas

Other

Technologies

Other

Company Type

Biotechnology – Diagnostics Biotechnology – R&D services Biotechnology – Therapeutics

State of Ownership

Private

Sponsorship Group

Networker

Topics

Editions participated in:

June 2020